A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503060-33-00

Acronym

NGM707-IO-101

Enrollment

Registered

2023-07-04

Start date

Unknown

Completion date

2025-01-14

Last updated

2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or Metastatic Solid Tumor Malignancies

Brief summary

" Treatment-emergent AEs characterized by type, frequency, severity (graded by NCI CTCAE v5.0), timing, seriousness, and relationship to study drug", " Objective tumor response (ORR) as per RECIST v1.1"

Detailed description

" Trough concentrations of NGM707 for selected cycles", " Incidence and titers of ADA and nAb against NGM707", " DCR, DOR, PFS as per RECIST v1.1 as assessed by the Investigator and overall survival "

Interventions

DRUGNGM707

DRUGpembrolizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
" Treatment-emergent AEs characterized by type, frequency, severity (graded by NCI CTCAE v5.0), timing, seriousness, and relationship to study drug", " Objective tumor response (ORR) as per RECIST v1.1"	—

Secondary

Measure	Time frame
" Trough concentrations of NGM707 for selected cycles", " Incidence and titers of ADA and nAb against NGM707", " DCR, DOR, PFS as per RECIST v1.1 as assessed by the Investigator and overall survival "	—

Countries

France, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026